Derek Semmler

Our session at ASUG Minnesota highlights how AI-driven insights are reshaping the Revenue Growth Management lifecycle, from Trade Promotion Predictive Modeling and Analytics, Actualization of Trade Performance to Intelligent Claims Management. Thrilled to see how IAP’s technology continues to help our clients achieve smarter, faster, and more sustainable growth. #SAP #DigitalTransformation #Leadership #SAPCCM #RevenueGrowthManagement #IncentiveManagement #S4HANA #ASUGCommunity #B2B #CustomerSuccess #TradeManagement #CPG #SalesProcesses #CustomerBusinessPlanning #SalesFinanceManager #SalesDirector #TradeFinance #SalesFinance #TradePromotionPlanningandManagement #Indirect #Wholesalers #Distributors #Minnesota

6

There’s a lot of wisdom in this insightful blog by Amy Saunders; worth a read. It’s brand planning season and her practical tips are spot on. Whatever you are thinking about for 2026, to quote Amy, it’s all about “data, data, data”.

14

Let’s talk about something that quietly threatens the success of clinical trials: protocol deviations. This document explores how ClinFocus, together with Medidata Solutions, helps clinical research teams detect, track, and address protocol deviations early,  before they escalate using real-time validation, automated alerts, and proactive data oversight. If you’re involved in clinical trials, this is a conversation worth having: it’s not just about collecting data it’s about ensuring the integrity of that data from start to finish. For questions or more information please contact us at info@clinfocus.com #ClinicalResearch #DataIntegrity #EDC #Medidata #ProtocolDeviation #ClinicalTrials

55

10 Comments

What’s one way to enhance accurate and reliable data collection in your cardiovascular trial? Effective site management. Learn more about the various ways to transform your next cardiovascular study in our white paper: https://bit.ly/46MpJou

1

How do we know if a site network is the right fit for our oncology studies? Worldwide’s Dr. Matt Cooper and Scott Palmese share their insights in this new article by MedCity News, outlining four traits every sponsor should consider to ensure a site network aligns with the strategic goals of their studies. https://bit.ly/4oV0YwY

5

If you're headed to SCOPE you must have a look at what the team at TrialScreen are doing. Their approach to connecting patients with research options that will benefit their health and study outcomes is novel and will be successful.

25

Another strong signal that the CDMO sector isn’t just growing, it’s set to take off. 🚀 INCOG BioPharma Services just announced a $200m expansion of its Fishers, Indiana campus, with plans to grow the team to nearly 1,000 employees by 2030. 🇺🇸 On the surface, this is about scale: 💉 Expanded injectable manufacturing capacity 💉 A 21-acre, purpose-built campus 💉 Hundreds of high-value jobs across operations, engineering and quality But step back, and this is really about confidence. Confidence from global biopharma partners driving sustained demand. Confidence in quality systems and execution. And confidence that investing in people is as critical as investing in steel and equipment. What I find most interesting is what this means for talent. As CDMOs scale at this pace, success won’t come from capacity alone. It will come from organisations that: • Plan talent pipelines early, not reactively • Build quality-led cultures that scale with growth • Treat people as long-term partners, not short-term hires INCOG’s expansion is another reminder that the future of pharma services will be won by those who align infrastructure, partnerships and talent strategy. Huge congratulations to the INCOG BioPharma team on a landmark investment and another strong signal of where this industry is heading. 📈

233

10 Comments

The $10 Million Dollar door stop Most ‘Successful’ Transformation projects Aren’t Actually Successful — They’re Just On Time and On Budget If you’ve been around executive teams long enough, you’ve seen this pattern: A major infrastructure or modernization program wraps up. The final status deck says: ✔ On time ✔ On budget ✔ Scope delivered There’s a sense of closure. Sometimes even celebration. And yet, months later, very little has actually changed in how the business operates. Productivity looks largely the same. Costs haven’t meaningfully moved. Legacy systems are still quietly running in the background. Everyone in the room knows this happens. But we still declare victory and move on. Why? Because “on time and on budget” has become a socially acceptable proxy for success, even though most leaders intuitively understand it only measures how well the project was executed, not whether the business actually benefited. This creates what I think of as success theater: The appearance of transformation without validated transformation. Over the next few posts, I’m going to unpack why this happens and what leaders can do differently. Part 1: Why “on time, on budget” became our definition of success Part 2: How delivery metrics get confused with ROI Part 3: Why business transformations quietly become IT projects Part 4: What happens when adoption is ignored (a real-world example) Part 5: Why multi-year ROI gets judged on one-year scorecards Let’s be honest — we’ve all seen this. What’s the most “successful” transformation program you’ve been part of that checked every PMO box… but, a year later, hadn’t materially changed how the business actually operates? What was supposed to improve? What actually changed? #Leadership #DigitalTransformation #BusinessTransformation #ITLeadership #ROI #ValueRealization

5

🎬 The Pathfinder Framework: A Better Way to Start Complex Projects Most project timelines are reverse-engineered from a go-live date someone guessed before they understood the work. That’s how teams get locked into fictional plans… and spend 3x the budget fixing what should’ve been discovered upfront. There’s a better way. ⸻ 🔭 Introducing the Pathfinder Framework A delivery model that earns clarity before making commitments. Instead of guessing timelines on day one, we split the work into Exploration Modules, each focused on uncovering: • Data sources and gaps • Compliance scope and validation risks • Integration pathways • AI readiness • Operational unknowns Each module includes input from business, admin, executive, and technical stakeholders—because every layer holds part of the truth. We timebox the exploration. Document what we learn. Assign a confidence level. And only when we hit 80–90% certainty… 👉 Then we plan the build. ⸻ No more fiction-based roadmaps. No more last-minute “we didn’t know that” moments. Just practical, high-trust delivery—especially for regulated, data-heavy, or legacy-tangled projects. ⸻ If you’ve been burned by fixed timelines that didn’t match reality, let’s talk Pathfinder. #projectmanagement #pathfinderframework #deliverystrategy #digitaltransformation #dataquality #compliancesolutions #techleadership

2

Excellent breakdown by Poonam Pathak and Erin Williamson of how platforms like UBC’s Tableau Data Analytics are transforming pharmacovigilance oversight. Centralized data, real-time access, tailored dashboards, and intuitive visualizations are no longer ‘nice to have’—they’re essential for compliance and decision-making.

4

Seamless and secure access to real-world data is critical for driving smarter, faster decisions in precision medicine. That’s why we’re proud to partner with AWS and Datavant on the launch of Datavant Connect, a transformative data discovery platform that’s reshaping how life sciences companies access and assess RWD. As a founding member, Diaceutics PLC is honored to contribute our unique lab and genetic insights to help uncover clinically relevant patient cohorts—often invisible through claims data alone. Special thanks to Praveen Haridas and Arnaub Chatterjee for making this milestone possible. Together, we’re building a more connected, privacy-conscious future for healthcare. #RWD #cleanrooms #precisionmedicine

15

🧪 AI meets innovation in clinical trials. This weekend on Inside the Blueprint, we’re spotlighting Medidata Solutions, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry. With a secure, global cloud platform and data analytics tools supporting over 36,000 trials, Medidata is helping biopharma companies bring life-changing therapies to market faster, safer, and smarter. Don’t miss their segment: ▶️ Saturday, 11/22 at 4:30 PM ET on Fox Business ▶️ Sunday, 11/23 at 2:30 PM ET on Bloomberg US #InsideTheBlueprint #Medidata #AIinHealthcare #ClinicalTrials #DigitalInnovation #LifeSciences

30

1 Comment

This is a fantastic article offering a comprehensive insight into the complex and obscure realm of alternative funding programs (AFPs). https://gag.gl/MLgTBa

4

In a compelling new interview with Fierce Biotech, Isagani Chico, MD shares insights on the evolving oncology drug development landscape and the strategic role of contract research organizations (CROs). https://gag.gl/voobQz #oncology #drugdevelopment

13

Recently, I had the honor of speaking at Reuters Events Pharma Customer Engagement USA in Philadelphia on purpose-driven growth and empowering teams for the future. From growing up in the Midwest to the start of my career as a chemical engineer to now leading a global commercial business unit, it was a great opportunity to reflect on my 25-year career journey and share some lessons: 🧭 Leaders are the compass, not the GPS. My role is not to have all the answers but to set the vision and create a culture. Doing so creates the right environment to rally and empower your teams to drive performance. 📈 Career journeys are rarely linear, and I’m incredibly grateful to the leaders who took a chance on me. When you get those opportunities, capitalize and execute. 🔍Look for the individuals with grit. The self-starters, the ones who stay curious, raise their hands and then deliver with drive. Despite not checking the traditional boxes, people who can think critically, collaborate deeply, and move with the business as it transforms are all the all-stars you want on your team. The last lesson is that it’s all up to you. You are responsible for taking initiative and never giving up. Thank you to Reuters for hosting this event and to those that have reached out following. Leave a note about what lessons you’ve learned to continue the conversation.

121

7 Comments

Partnership Announcement: Safety Partners and Trinity Consultants The transparency between EHS consultant and client has been a significant challenge in our industry. Today, that changes. SciSure is now partnered with Safety Partners and Trinity Consultants to deliver expert EHS consulting and regulatory compliance inside SciSure’s Scientific Management Platform (SMP). We are thrilled to partner with Jennifer Reilly, Lauren Laidlaw, and team. Together, we deliver a trusted, fully digital experience that clients expect and deserve. The future model of EHS consulting has arrived. Please follow us at SciSure for more updates. Link in comments. #EHS #Compliance #lifesciences #SafetyPartners #SciSure #TrinityConsultants

78

6 Comments

Those of us working across pharma and biotech understand the challenges around the time it takes to get new medicines to patients. This is why I'm very excited to see the announcement of the partnership between CCX and Model N, as it has real potential to help accelerate market access and product launch by bringing together CCX's market-access-specific planning capabilities with Model N's pricing, tender and revenue management solution. Combining not just the solutions, but also the knowledge and expertise of these two teams, will enable streamlined workflows, better scenario planning, and faster development and execution of global market access and pricing strategy. This is a big step forward in the early commercialisation space and one I will be watching with keen interest. I'm also sure that progressive market access leaders not already working with CCX and Model N will now take a much closer look at this offering! #MarketAccess #PricingStrategy #EarlyCommercial #Launch #PartnershipNews

19

1 Comment

In recent days, several colleagues have reached out regarding news about compliance allegations involving a different company named “Delve.” To clarify, these reports are unrelated to Delve Health. Our work focuses on clinical trial execution, digital endpoint operations, and longitudinal data integrity. That said, the broader conversation highlights an important structural dynamic within clinical research. As protocols become more complex and remote data capture becomes more prevalent, the industry is increasingly distinguishing between documented compliance readiness and sustained operational compliance performance. In practice, compliance maturity tends to follow execution maturity. Organizations that demonstrate durable performance characteristics, consistent participant engagement, stable device adherence, and complete longitudinal datasets - typically scale more effectively than those that attempt to scale ahead of operational proof points. This is why we have long believed in a phased execution model: crawl → walk → run Operational reliability first. Measured expansion second. Scaled deployment only after sustained performance is demonstrated. In an environment where digital infrastructure is evolving rapidly, execution discipline is becoming a primary determinant of study success. Compliance, in this context, is not a milestone to be achieved, but a capability to be continuously maintained. We welcome perspectives from peers and sponsors navigating similar shifts in trial design and execution. #ClinicalTrials #ClinicalOperations #DigitalEndpoints #TrialExecution #MedTech #RWE #PatientEngagement

7

1 Comment